VAL-101

N/A

Report date: 2025/01/26 15:18:23
NME

Base Information

Drug NameVAL-101
Drug Alias NameBCL2-targeting cancer therapy (ValiPharma/Cancer Research Technology)BCL2-targeting cancer therapy (Chronos/Cancer Research Technology)VAL-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesValiPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGerman Cancer Research Center (Dkfz)ValiPharma LtdCancer Research Technology
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A